Table 2.
The impact of HDACs on each DDR mechanism and their targets. The last column shows some of the selective HDACs inhibitors that are used in pre- and clinical setting in cancers.
| DDR Components | Cellular Procedures—DDR | HDAC Inhibitors | |
|---|---|---|---|
| HDAC1 | ATM, ATR, H3K56, H4K16, P53, Ku70, APE1/Ref1, CtIP | NHEJ HR Chromatin remodeling Apoptosis |
MS-275 CBUD-1001 |
| HDAC2 | H3K56, H4K16, Ku70 | apoptosis chromatin remodeling | |
| HDAC3 | H3K9 and K14, H4K5 and K12 | Chromatin remodeling | |
| HDAC4 | 53BP1 | ||
| HDAC6 | Ku70 GADD153 | Apoptosis | ACY-1215 ACY-241 |
| SIRT1 | H3K9, H4K16, P53, NBS1, XPA, Ku70, FOXO, WRN, XPC, RelA/P65,APE1/Ref1, TIP60, DNMT1, P300 | NER BER NHEJ HR Chromatin remodeling apoptosis |
|
| SIRT3 | H4K16, Idh2 | Chromatin remodeling oxidative stress | |
| SIRT6 | CtIP, XPA DNA PKs H3K9, H3K56 | HR BER NHEJ Chromatin remodeling |
OSS-128167 |